|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/00 | |
| A61K 38/03 | |||
| A61K 38/04 | |||
| A61P 27/02 |
| (11) | Patento numeris | 2627346 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11775734.4 |
| Europos patento paraiškos padavimo data | 2011-10-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-08-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-03-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/005172 |
| Data | 2011-10-14 |
| (87) | Numeris | WO 2012/048893 |
| Data | 2012-04-19 |
| (30) | Numeris | Data | Šalis |
| PCT/EP2011/0003 | 2011-01-25 | WO | |
| PCT/EP2010/0062 | 2010-10-14 | WO |
| (72) |
COMBETTE, Jean-Marc, FR
DELOCHE, Catherine, CH
ABADIE, Claire, FR
|
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
| (54) | CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR USE IN THE TREATMENT OF UVEITIS |
| CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR USE IN THE TREATMENT OF UVEITIS |